Company News
Great News | Fill the Market Gaps! LNC's 2nd Innovative Radionuclide drug was Approved for Clinical Trial

On Dec. 19, 2023, LNC received the IND approval from the NMPA for the 18F-LNC1005 Injection, and will enter the clinical trial soon.
2022-12-21
17:49
LNC Received the IND Approval for its First Self-Developed R&D Radionuclide Product

On Jul. 29, LNC received the IND approval for the 18F-LNC1001 Injection form the NMPA, and will enter the clinical trial soon.
2022-07-30
10:21
+86-0535-6391521
DC Pharma Wechat Official Account
Employee Daily Life Platform
About Us About Us Milestones Management Team
Innovative R&D Products under development R&D-Platform
News Center Company News Media News
Join Us Talent Cultivation Jobs Life
Contact Us
Copyright 2022 Yantai Lannacheng Biotechnology Co., Ltd. All Rights Reserved.